Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
View Older Stories View More Recent Stories
-
Zynerba Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference
-
Everbridge to Present at Upcoming Investor Conferences
-
Apple nears $1 trillion as bright forecast highlights future demand
-
Xencor to Present at Upcoming Investor Conferences
-
CORRECTING and REPLACING Catasys to Present at the Canaccord Genuity 38th Annual Growth Conference
-
Heska to Present at Canaccord Genuity 38th Annual Growth Conference on August 8th
-
Correvio to present at the Canaccord Genuity 38th Annual Growth Conference
-
Aldeyra Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference
-
KemPharm to Present at Canaccord Genuity 38th Annual Growth Conference
-
InMed to Present at the Canaccord Genuity 38th Annual Growth Conference
-
iRobot CEO to Speak at Upcoming Investor Conferences
-
AVEO Oncology to Present at the Canaccord Genuity 38th Annual Growth Conference
-
Deciphera Pharmaceuticals, Inc. to Present at the 38th Annual Canaccord Genuity Growth Conference
-
Apple (AAPL) PT Raised to $220 at Canaccord Genuity
-
CERES Coin to Present at 38th Annual Canaccord Genuity Growth Conference in Boston
-
Civitas Solutions, Inc. to Present at Canaccord Genuity Growth Conference in August
-
Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference
-
Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference
-
ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference
-
Profound Medical to Present at the Canaccord Genuity 38th Annual Growth Conference
-
Profound Medical to Present at the Canaccord Genuity 38th Annual Growth Conference
-
Orthofix to Present at Canaccord Genuity Growth Conference
-
Shopify (SHOP) PT Raised to $165 at Canaccord Genuity
-
MasTec Senior Management at Canaccord Genuity and Jefferies Investor Conferences in Boston and New York
-
Merit Medical to Present at Two Conferences in August
-
Kornit Digital to Present at the Canaccord Genuity 38th Annual Growth Conference
-
Datawatch To Participate in Canaccord Genuity 38th Annual Growth Conference
-
Ameresco to Present at 38th Annual Canaccord Genuity Growth Conference in Boston on August 8
-
Pear Therapeutics to Present at Canaccord Genuity 38th Annual Growth Conference
-
Xeris Pharmaceuticals to Present at Two Upcoming Investor Conferences
-
Oncolytics Biotech® to Present at the Canaccord Genuity 38th Annual Growth Conference
-
Xeris Pharmaceuticals to Present at Two Upcoming Investor Conferences
-
REISSUE - ABcann to Acquire Leading B.C. Producer Canna Farms
-
Oncolytics Biotech® to Present at the Canaccord Genuity 38th Annual Growth Conference
-
Interim Results
-
ABcann to Acquire Leading B.C. Producer Canna Farms
-
Aegion Corporation to Present at Upcoming Investor Conferences
-
Atlassian to Present at Upcoming Investor Conferences
-
Kratos to Present at the Canaccord Genuity Growth Conference
-
Aspen Aerogels to Present at the Canaccord Genuity Growth Conference
-
Veracyte to Present at the Canaccord Genuity 38th Annual Growth Conference
-
Tactile Medical to Present at the Canaccord Genuity 38th Annual Growth Conference
-
Merit Medical Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Over-Allotment Option
-
Boston Scientific to Participate in 38th Annual Canaccord Genuity Growth Conference
-
Maricann Group Announces Amendment to Terms of Private Placement
-
Quanterix to Present at the Canaccord Genuity 38th Annual Growth Conference
-
Apricus Biosciences (APRI) Announces Merger Agreement with Seelos Therapeutics
-
Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders
-
Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders
-
DLH to Present at the Canaccord Genuity Conference on August 8

